GG 705 (Ranitidine 150 mg)
Pill imprint GG 705 has been identified as Ranitidine hydrochloride 150 mg.
Ranitidine is used in the treatment of gerd; erosive esophagitis; duodenal ulcer; zollinger-ellison syndrome; eczema (and more), and belongs to the drug class H2 antagonists. There is no proven risk in humans during pregnancy. Ranitidine 150 mg is not a controlled substance under the Controlled Substance Act (CSA).
- GG 705
- 150 mg
- 8.00 mm
- Rx and/or OTC
- Drug Class:
- H2 antagonists
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Sandoz Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- D&C Red No. 30
hypromellose 2910 (3 mPa.s)
sodium starch glycolate type A potato
|NDC Code||Manufacturer / Repackager|
|51079-0879||UDL Laboratories Inc|
|63739-0266||McKesson Packaging Services|
|66267-0188||Nucare Pharmaceuticals Inc (repackager)|
|57866-6930||Direct Dispensing Inc (repackager)|
|67544-0049||Prepak Systems Inc (repackager)|
|21695-0109||Rebel Distributors Corp (repackager)|
|23490-6249||Palmetto State Pharmaceuticals Inc (repackager)|
Note: Inactive ingredients may vary.
More about ranitidine
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.